- Details
- Rashid Sayyid and Zach Klaassen review the 2024 NCCN Guidelines for managing very low-risk prostate cancer. Dr. Sayyid defines very low-risk prostate cancer using criteria like T1C stage, PSA levels, and biopsy characteristics. The updated guidelines simplify management based on life expectancy: patients with 10 years or more are recommended active surveillance, while those with less are advised o...
|
- Details
- Zach Klaassen hosts a multidisciplinary roundtable discussing the NCCN Prostate Cancer Guidelines with a focus on the ArteraAI prostate test. Joined by Dr. Dan Spratt, Dr. Alicia Morgans, and Dr. Neal Shore, they explore the importance of risk stratification in prostate cancer, highlighting the superior predictive and prognostic capabilities of the ArteraAI test compared to traditional methods. Th...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, specifically looking at radical prostatectomy for prostate cancer. The NCCN guideline panel states radical prostatectomy is an appropriate choice for any patient whose cancer appears to be clinically localized to the prostate. However, it is known tha...
|
- Details
- Zachary Klaassen discusses the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, specifically focusing on the utilization of Lutetium PSMA in metastatic castration–resistant prostate cancer (mCRPC) patients. Biographies: Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta University, G...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, specifically looking at radiation therapy and focusing on an overview of brachytherapy, proton therapy, and radiation for distant metastasis. The NCCN Guideline Panel recommends radium-223 as a Category 1 treatment option in men w...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, specifically looking at radiation therapy and focusing on an overview of the role of radiotherapy, a discussion of external beam radiotherapy, and a brief discussion of stereotactic body radiation therapy. The NCCN guidelines emphasize that SBRT and I...
|
- Details
- This UroToday journal presented by Zachary Klaassen and Christopher J.D. Wallis discusses Version 1 2022 Prostate Cancer guidelines discussing the comparison of treatment options for localized disease followed by a discussion on local therapies and finally disease monitoring. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toront...
|
- Details
- Christopher Wallis and Zachary Klaassen review the 2022 NCCN Clinical Practice Guideline in Oncology Prostate Cancer reviewing the epidemiology, initial diagnosis, and life expectancy of men with prostate cancer. Dr. Klaassen provides an overview of prostate cancer epidemiology, details the initial prostate cancer diagnosis, and highlights the importance of estimating life expectancy in these pati...
|
- Details
- Christopher Wallis and Zachary Klaassen review the NCCN Clinical Practice Guideline in Oncology Prostate Cancer and in this conversation the pair focuses on nuances in advanced prostate cancer, including neuroendocrine disease, bone, and visceral metastases, and treatment sequencing. In the context of bone metastases, Dr. Wallis highlights a variety of data that has been published over the last fe...
|
- Details
- In this UroToday Journal Club presentation Christopher Wallis and Zachary Klaassen, continue their in-depth review of the NCCN clinical practice guidelines in prostate cancer focusing on risk stratification for clinically localized disease. They focus on risk stratification for patients with prostate cancer. Dr. Christopher Wallis discusses the use of nomograms and the use of Tumor Multigene Molec...
|
